Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867020259710468096 |
|---|---|
| author | Yun Wang Yajing Wang Yiming Mu Yu Cheng |
| author_facet | Yun Wang Yajing Wang Yiming Mu Yu Cheng Yun Wang Yajing Wang Yiming Mu Yu Cheng |
| collection | Wiley Open Access |
| contents | Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study Yun Wang Yajing Wang Yiming Mu Yu Cheng Diabetes, Obesity and Metabolism Abstract Aims We aimed to compare renal outcomes between patients with type 2 diabetes mellitus (T2DM) who were treated with sodium‐glucose cotransporter 2 (SGLT2) inhibitors and those on other glucose‐lowering drugs under routine clinical practice. Materials and Methods IMPROVE was a multicentric, observational, prospective real‐world study conducted across 45 hospitals in China. Eligible patients were adults ≥18 years with T2DM for ≥12 months who were currently taking SGLT2 inhibitors or other glucose‐lowering drugs. Blood and urine samples were collected at baseline and 6 months. The primary endpoint was the rate of change of eGFR compared with the baseline level after 6 months. Results The study took place between September 2021 and September 2023. At baseline, mean glycated haemoglobin was 8.33%, and mean eGFR was 114.68 mL/min/1.73 m 2 . Among 5562 patients completing 6 months follow‐up, the mean eGFR change was +1.2 mL/min/1.73 m 2 in the SGLT2 inhibitors group versus −6.0 mL/min/1.73 m 2 in controls (difference 8.0, 95% CI 5.7–10.4; p < 0.0001). In the SGLT2 inhibitors group, the risk of an eGFR decline ≥25% was 18.9%, lower than the 22.8% observed in controls (RR 0.83, 95% CI 0.78–0.87). The composite outcome of improved glycaemic control plus stable renal function was achieved in 39.1% versus 35.0% (RR 1.12, 95% CI 1.06–1.18). Conclusions In this Chinese real‐world study of patients with T2DM, treatment with SGLT2 inhibitors was associated with a slower decline in kidney function compared with other glucose‐lowering drugs. 10.1111/dom.70413 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/dom.70413 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_dom_70413 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study Yun Wang Yajing Wang Yiming Mu Yu Cheng Diabetes, Obesity and Metabolism Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study Yun Wang Yajing Wang Yiming Mu Yu Cheng Diabetes, Obesity and Metabolism Abstract Aims We aimed to compare renal outcomes between patients with type 2 diabetes mellitus (T2DM) who were treated with sodium‐glucose cotransporter 2 (SGLT2) inhibitors and those on other glucose‐lowering drugs under routine clinical practice. Materials and Methods IMPROVE was a multicentric, observational, prospective real‐world study conducted across 45 hospitals in China. Eligible patients were adults ≥18 years with T2DM for ≥12 months who were currently taking SGLT2 inhibitors or other glucose‐lowering drugs. Blood and urine samples were collected at baseline and 6 months. The primary endpoint was the rate of change of eGFR compared with the baseline level after 6 months. Results The study took place between September 2021 and September 2023. At baseline, mean glycated haemoglobin was 8.33%, and mean eGFR was 114.68 mL/min/1.73 m 2 . Among 5562 patients completing 6 months follow‐up, the mean eGFR change was +1.2 mL/min/1.73 m 2 in the SGLT2 inhibitors group versus −6.0 mL/min/1.73 m 2 in controls (difference 8.0, 95% CI 5.7–10.4; p < 0.0001). In the SGLT2 inhibitors group, the risk of an eGFR decline ≥25% was 18.9%, lower than the 22.8% observed in controls (RR 0.83, 95% CI 0.78–0.87). The composite outcome of improved glycaemic control plus stable renal function was achieved in 39.1% versus 35.0% (RR 1.12, 95% CI 1.06–1.18). Conclusions In this Chinese real‐world study of patients with T2DM, treatment with SGLT2 inhibitors was associated with a slower decline in kidney function compared with other glucose‐lowering drugs. 10.1111/dom.70413 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study |
| topic | Diabetes, Obesity and Metabolism |
| url | https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70413 |